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Abstract: Multiscale computational modeling of drug delivery systems (DDS) is poised to 
provide predictive capabilities for the rational design of targeted drug delivery systems, includ-
ing multi-functional nanoparticles. Realistic, mechanistic models can provide a framework for 
understanding the fundamental physico-chemical interactions between drug, delivery system, 
and patient. Multiscale computational modeling, however, is in its infancy even for conventional 
drug delivery. The wide range of emerging nanotechnology systems for targeted delivery further 
increases the need for reliable in silico predictions. This review will present existing compu-
tational approaches at different scales in the design of traditional oral drug delivery systems. 
Subsequently, a multiscale framework for integrating continuum, stochastic, and computational 
chemistry models will be proposed and a case study will be presented for conventional DDS. 
The extension of this framework to emerging nanotechnology delivery systems will be discussed 
along with future directions. While oral delivery is the focus of the review, the outlined com-
putational approaches can be applied to other drug delivery systems as well. 
Keywords: Oral drug delivery, multiscale, computational modeling, continuum, computational 
chemistry, stochastic 
Introduction
Nanotechnology-based drug delivery systems (DDS) are a primary component of 
nanomedicine’s potential to improve human health. Over 70% bionanotechnology 
scientiﬁ  c articles focus on DDS (Webster 2006). Multifunctional nanoparticle drug 
carriers and nanostructured responsive drug matrices, in particular, have gained 
increasing attention (Kawasaki and Player 2005). Whether through nanotechnology 
or conventional technologies, advancements in drug delivery aim to improve patient 
treatment by enabling the administration of complex new drugs, improving the bio-
availability of existing drugs, and providing spatial and temporal targeting of drugs 
in order to dramatically reduce side effects and increase effectiveness. Through these 
achievements, patients and physicians could beneﬁ  t from personalized prescriptions, 
increased ease of administration, increased patient compliance, and reduced dosage 
frequency. 
This envisioned future of medicine demands quantitative, mechanistic models 
as tools to predict the complex interactions between drug, drug delivery system, and 
patient physiology. These models, by deﬁ  nition, must span broad scales of space and 
time. The purpose of this review is to present a multiscale framework for integrating 
existing computational approaches at the different scales of the drug delivery problem 
for both conventional and nanoparticles-based drug delivery. As oral delivery remains 
dominant over other possible routes (intravenous, oral, subcutaneous, nasal, vaginal, 
rectal or ocular), this review will focus on oral DDS. For this reason, interaction International Journal of Nanomedicine 2007:2(3) 316
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between the drug and the gastrointestinal (GI) tract be-
comes common to all problems considered and will receive 
particular focus. While the emphasis is on oral delivery, the 
multiscale computational approaches and framework out-
lined could be applied to other delivery modes as well.
Oral drug delivery systems
Deﬁ  ning the problem
Assessment of past drug development activities has 
estimated that ~39% of failures could be attributed to poor 
pharmacokinetics and ~11% to toxicity (Kennedy 1997; van 
de Waterbeemd and Gifford 2003). For this reason, the in silico 
prediction of the absorption, distribution, metabolism, excre-
tion and toxicity (ADMET) of potential new drugs in early 
stages of development has become a critical area of research. 
The success of high throughput screening, proteomics, ge-
nomics, combinatorial chemistry and biotechnology to create 
increasing numbers of novel therapeutic candidates further 
ampliﬁ  es the need for modeling. Despite the potential, the 
contribution of in silico computational approaches to the design 
of conventional drug delivery systems has so far been limited. 
Some commercial software such as GastroplusTM (Agoram et al 
2002) and iDEATM (Grass 1997) for ADMET prediction and 
others for toxicity prediction exist (see Green (Greene 2002) 
for a more complete list of commercial software). A good 
number of the models used in these tools are mostly rule-based 
limiting their application. In addition, the multi-functionality, 
complexity, and emergent properties of nanoparticle-based 
systems create additional and unique challenges. 
In their review (van de Waterbeemd and Gifford 2003), 
as well as others, assert a need for a new generation of 
mechanism-based models to provide sufﬁ  cient knowledge 
to successfully predict and simulate ADMET and drug 
action. The key mechanisms that govern the drug system 
occur across a wide range of scales in both space and 
time (Fig. 1). DDS design requires the quantification 
and prediction of the nano and microscale molecular 
interactions, microscale cellular mechanisms and macro-
scopic physiological effects in the targeting, entry and de-
livery processes at multiple scales. Each of these processes 
may be best modeled by different mathematical strategies. 
The grand challenge is to seamlessly integrate different model 
types across wide scales of space and time, and even allow 
multiple scales to be simulated concurrently.
Deﬁ  ning the drug delivery system
Both conventional and nanoparticle DDS aim to target speciﬁ  c 
cellular/tissue/organ sites, control the delivery of the active 
component at the desired rate, and to provide solutions to 
important problems of drug solubility, protection, side effects, 
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toxicity, and efﬁ  cacy. For purposes of this paper, the term 
‘conventional’ or ‘traditional’ DDS includes both immediate 
and controlled release systems achieved by incorporating 
drugs within bulk materials such as polymers or by altering 
the chemistry of the drug for example by prodrug formation. 
Examples of nanoparticles for DDS or medical diagnostics 
include but are not limited to dendrimers (Kitchens et al 
2005), shell cross-linked nanoparticles (Sun et al 2005; 
Thurmond et al 1996), functionalized polymer nanoparticles 
(Farokhzad et al 2006), inorganic nanocrystals (Akerman et al 
2002), and RNA nanoparticles (Khaled et al 2005).
The power of nanoparticles for oral drug delivery derives 
from two major advantages: an ability to form multi-func-
tional particles on size scale relevant to cells and an ability 
to design unique and emergent properties compared to bulk 
materials. Multi-functionality refers the integration of mul-
tiple capabilities or properties onto a single particle. These 
functions may include targeting by recognition (eg, cell type 
speciﬁ  c ligands-receptor interaction) (Popielarski et al 2005), 
targeting by external intervention (eg, photosensitization) 
(McCarthy et al 2005), properties for handling and sorting 
(eg, magnetic or chemical separation) (Dresco et al 1999), 
imaging and identiﬁ  cation (optical properties, quantum dots 
etc) (Lewis et al 2006), increased bioavailability, solubility, 
or circulation time of drug (Gref et al 1994; Manjunath and 
Venkateswarlu 2005), and selective delivery of drug payload. 
Multi-functionality can be achieved by the conjugation at 
the surface, layering (Prow et al 2005), or by the design 
and synthesis of the nanoparticle core itself. Nanoparticles 
from this point of view are a composite of molecules and 
materials each having at least one advantageous property 
or function. The nanoscale size of the particles also means 
that the resulting novel properties of materials at this scale 
can be utilized. Quantum dots, gold core/shell particles and 
superparamagnetic particles are all good examples.
Establishing a framework 
for multiscale modeling of DDS
Complete models need to consider key physical, chemical, 
and the often omitted, biological processes at the spectrum 
of scales in temporal and spatial dimensions. The framework 
should address the processes and interactions involved during 
delivery process at different scales using three fundamental 
elements:
1.  Macroscale changes of the drug delivery vehicle. As 
the delivery vehicle transits the gastrointestinal (GI) tract 
or the systemic circulation, change and deformation, 
will impact drug availability. For conventional delivery 
and for nanoparticles delivered in a bulk carrier, this is a 
macroscale problem. Prediction of these changes requires 
continuum based modeling (eg, represented as differential 
equations), which address the different processes such 
as diffusion, dissolution, degradation and swelling. The 
application of a moving boundary and free boundary 
approaches are essential.
2.  Nano and microscale molecular interactions between 
drug, vehicle, GI tract, and target site. Along the path 
of the drug, particle and carrier, many molecular processes 
and interactions are critical. These include the speciﬁ  c 
interaction of the delivery polymer/system with the drug, 
enzymatic action on the drug/particle/carrier in the GI tract, 
drug/particle/carrier interactions with the epithelial inter-
face at the absorption site, receptor/transporter/membrane 
at the target site either in the GI tract or other organs after 
absorption at the nano and micro levels. This requires 
computational chemistry approaches such as molecular 
dynamics (MD) and mesoscale modeling (modeling at 
length and time scales between MD and continuum me-
chanics) for the problems beyond reach of MD.
3.  Biological and delivery system variability at all scales. 
Prediction of the effect of variability that arises from 
biological sources such as inter/intra subject variability 
or inherent variability in the delivery system such as 
polymer coating non-uniformity both at macro and micro/
nano levels. These issues can be addressed by employing 
stochastic approaches.
Linking and modeling across 
the scales
In order to simulate the entire system from drug to patient, 
the three elements presented above must be integrated and 
linked. Figure 2 depicts a multiscale computational frame-
work for model-based simulation of the entire system from 
drug design to patient physical and pathological conditions. 
In this framework, the system consists of three components: 
the drug, the delivery system and the patient. Information 
from these components is gathered and compiled by means 
of mechanistic approaches into a multiscale mathematical 
model. The challenge of multiscale modeling is the transition 
from one space-time scale to another. With respect to spatial 
scale this can be from nano to micro or micro to macro and 
with respect to time from picoseconds (eg, such as in MD) to 
seconds or minutes, for instance. For mechanistic models, the 
nature of coupling of the physical, chemical and biological 
processes at each scale determines how the computational 
methods should be linked. International Journal of Nanomedicine 2007:2(3) 318
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Of particular interest to the interaction of the delivery 
system at the biological interface is discrete-to-continuum 
coupling including two main categories: information-
passing (sequential, serial, hierarchical, parameter passing) 
and concurrent (embedded, integrated, hand-shake) (Fish 
and Chen 2004a). 
In the information-passing approach, the information 
gained in the lower scale is transferred on to the higher 
scale. For example, molecular dynamics may be used to 
predict physical parameters, such as diffusivity (eg, of a drug 
molecule in the carrier material or across a lipid bi-layer) or 
solubility (eg, of the carrier or drug at the biological interface 
as a function of physiological pH) that may be employed to 
compute higher level or scale continuum transport models. 
It is noteworthy that this approach is valid as long as the 
information obtained from the lower space-time scale can 
be summarized into a ﬁ  nite set of parameters and represent 
the rigorous reduction of the enormous degrees of freedom 
of the lower length (space or time) of scale. In the context 
of discrete-to-continuum coupling, the Generalized Math-
ematical Homogenization (GMH) theory (Chen and Fish 
2006) can be mentioned among the information passing 
bridging techniques. The GMH constructs an equivalent 
continuum description directly from discrete (such as MD) 
equations. In general the mathematical homogenization 
theory makes the assumption that the ﬁ  ne scale is locally 
periodic and is composed of four steps (Chen and Fish 
2006): (i) solving a sequence (various orders) of unit cell 
problems; (ii) computing effective coarse-scale properties; 
(iii) solving the coarse-scale problem; and (iv) localizing 
(or post-processing) the ﬁ  ne scale data.
In the concurrent or embedded approach, the multiple 
scales are resolved simultaneously in different portions 
of the domain of interest. More theoretical and computa-
tional effort is required in this approach than the former. 
The information between the different hierarchical models is 
communicated via the domain decomposition methods where 
the system response is separated into local (discrete) and 
global (continuum) effects. Among the concurrent bridging 
techniques the space-time multilevel method (Fish and Chen 
2004b) can be mentioned. In the context of drug delivery this 
approach can be applied, for example, to the prediction of 
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Figure 2 A framework for multiscale modeling of entire drug delivery systems using information from drug and vehicle properties, disease pathology, and patient 
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biodegradable polymer delivery devices where the polymer 
is degraded until a critical molecular weight is reached before 
solvation begins. The bond breaking at the solvent-polymer 
interface can be described by quantum mechanical model 
of bonding while the rest of the domain is described with 
empirical potential. 
Given that mechanisms at each level in the drug delivery 
design process form a vast and complex network of dynami-
cally interacting heterogeneous components, the multiscale 
modeling can involve other multiscale approaches such as 
continuum-to-continuum coupling between different time 
scales. 
The next sections will introduce and summarize three 
basic modeling approaches and their applicability to the 
different scales relevant to oral drug delivery, including 
examples of nanoparticle processes. This review is by no 
means exhaustive, but rather representative of the variety 
of approaches at each scale, which can be integrated into 
the multiscale framework. A case study will then provide a 
speciﬁ  c example of this integration.
Continuum approaches at the 
micro and macro scales
Polymer systems for controlled or 
triggered release 
A wide range of polymers have demonstrated controlled or 
triggered release using different rate controlling mechanisms 
such as diffusion (Langer and Peppas 1983; Costa et al 2001), 
swelling (Siepmann and Peppas 2001), erosion (Siepmann 
and Gopferich 2001), ion exchange (Jeong et al 2006) or 
any combination of these in response to environmental 
stimuli. As a result a large number of mathematical, typi-
cally continuum, models and theories have been developed 
to describe the mass transport mechanisms and chemical 
processes that occur within polymer systems. (Kanjickal 
and Lopina 2004) have compiled an excellent review on the 
continuum based computational approaches for polymeric 
drug delivery systems. The classiﬁ  cation of the models is 
summarized in Figure 3. 
In general, the mechanistic models can be represented 
by a single equation incorporating reaction-transport, ion 
exchange and a source term with pertinent different initial 
and boundary conditions. 
 
∂
∂ () ⋅ () ⎡ ⎣ ⎤ ⎦ =∇ () ⋅
∇ () + () ∇ ⎛
⎝ ⎜
⎞
⎠
t
crt rt Dc
rt crt z crt
F
RT
,,
(,) , ,
ε
εϑ ⎟ ⎟+ν
     
(1)
Where c(r,t) is the concentration of diffusing species, ε(r,t) is 
the porosity along the diffusion pathway, D(c) is the effective 
diffusion of the species, r is an arbitrary coordinate system, 
t is time, z is the valence, F is Faraday constant, R is gas 
constant, T is absolute temperature, ϑis electric potential and 
v is the net sum of synthesis and degradation of the species. 
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Convective ﬂ  ows inside the delivery system are practically 
non-existent thus no convective term included in Eq. (1). The 
boundary conditions can generally be represented by a form 
that accounts for the ﬁ  rst second and third kinds given by:
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(2)
where α, β, and γ may be zero, unity or some function of the 
system’s thermodynamics or transport properties.
This model contains a large number of parameters 
and non-linearities associated with the different chemical and 
physical processes. Moreover, as the dosage form transits in 
the GI tract its physical geometry continually deforms due to 
swelling and erosion, which affect the drug release kinetics. 
These changes create a moving boundary problem, as the 
change in geometry should be accounted for as the simulation 
progresses. These factors generally pose difﬁ  culty in solving 
the system of equations using analytical techniques. For such 
detailed models, one turns to numerical techniques such as 
Finite element method (FEM) (Reddy 2005), Finite volume 
method (FVM) (LeVeque 2002), Finite difference, boundary 
element methods (Kane 1993) and recently meshless meth-
ods (Atluri and Shen 2002). Of these methods, FEM is the 
preferred due to its ﬂ  exibility in handling irregular geometric 
shapes and boundary conditions. In addition, general purpose 
computer programs can be developed easily to analyse vari-
ous kinds of problems. 
In FEM, a geometrical model of the delivery system is 
discretized into a ﬁ  nite number of elements, interconnected 
by a ﬁ  nite number of nodes. The continuous concentration 
ﬁ  elds in the domain is approximated by a polynomial that 
interpolate in the nodal values. Applying approximation 
techniques such as the Galerkin weighted residual method 
a system of ﬁ  rst order differential equations is obtained 
(Segerlind 1984).
  C
u
Ku f
d
dt
+=  (3)
where C is the global capacitance matrix, K the global 
conductance matrix, f the global load vector and u the 
vector which contains the approximate concentrations at 
the nodes. Several numerical integration schemes such as 
the single step (eg, the implicit Euler and the Runge-kutta) 
and multistep methods can be used to solve this ﬁ  rst order 
time domain ordinary differential equation (ODE). The 
choice among these methods can be based on the stability 
and accuracy of the method for a speciﬁ  c class of problems 
and can be implemented in a ﬁ  xed or adaptive time step 
schemes.
The classical problems in partial differential equations 
involve solving an equation within a ﬁ  xed spatial region. 
When attempting to model the changing and deforming 
dosage form as it transits the GI tract, however, the domain 
will also vary and must be determined. Such problems, for 
which the solution of a partial differential equation is sought 
in a region which is itself varying in an unknown manner, 
are referred to as moving boundary problems. (Li et al 
2005) classify numerical solutions of moving boundary 
problems into two categories, moving grid methods and 
the ﬁ  xed grid methods. Each method has its own advan-
tages and disadvantages. Methods in the context of ﬁ  xed 
grid approach, such as the front-tracking (Tryggvason and 
Unverdi 1990, 1992), surface tracking (Hirt and Nichols 
1981; Gueyfﬁ  er et al 1999; Scardovelli and Zaleski 1999), 
and volume tracking (the volume of ﬂ  uid (VOF) method) 
(Popinet and Zaleski 1999; Renardy and Renardy 2002) 
methods are capable of simulating very complex interface 
motion. New algorithms have also been developed to im-
prove the accuracy in the treatment of boundary conditions 
(Ryskin and Leal 1984; Maury 1999; Fast and Shelley 
2004). Moving grid methods employ a so-called boundary-
ﬁ  tted grid system (Donea et al 2004; Knobbe 2004; Li et al 
2005; Nithiarasu 2005). This method has the tremendous 
advantage that the boundary condition is treated neatly 
and resolved accurately, because the moving boundary 
coincides with one line of the numerical grid. 
One example from the latter category is the Arbitrary 
Lagrangian-eulerian approach. This boundary tracking 
method attempts to secure the best features of the Lagrangian 
(where the computational grid follows the material move-
ment, thus unable to follow large distortions) and Eulerian 
(in which the computational mesh is ﬁ  xed and the continuum 
moves with respect to the grid; though allows large distor-
tions in the continuum but at the expense of precise interface 
deﬁ  nition) approaches while minimizing their respective 
drawbacks. This allows the spatial conﬁ  guration the mate-
rial conﬁ  guration move and deform independently over a 
ﬁ  xed referential conﬁ  guration which gives this approach 
the ability to follow large deformations without recourse to 
frequent remeshing operations reducing the computational 
cost substantially. For details of the ﬁ  nite element analysis 
– Arbitrary lagrangian-eulerian method and implementation, 
the reader is referred to (Donea et al 2004; Knobbe 2004; 
Li et al 2005; Nithiarasu 2005). International Journal of Nanomedicine 2007:2(3) 321
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Kinetic and biophysical models of 
nanoparticle transport 
Experimental results suggest that endocytosis is a primary 
transport mechanism for particle uptake (Russell-Jones et al 
1999; Kenneth et al 2005; Kitchens et al 2005, ). As a result, 
endocytotic uptake has been a focus of several continuum 
models.These models can generally be classiﬁ  ed as kinetic 
models and biophysical models. The kinetic models describe 
the internalization of particles based on classic kinetic theory 
of biochemical binding and reaction, while biophysical 
models attempt to describe the biophysical aspects of uptake 
and transport.
Kinetic models with varying degree of details were 
proposed from early 80’s for bare and surface func-
tionalized nanoparticles (Wiley and Cunningham 1981, 
1982; Zigmond et al 1982; Gex-Fabry and DeLisi 1984; 
Shimizu and Kawashima 1989; Lauffenburger and 
Linderman 1993; Nunes-Correia et al 1999; Eliaz et al 
2004). A standard kinetic model of ligand-induced en-
docytosis, such as that by Lauffenburger and Linderman, 
(Lauffenburger and Linderman 1993) can be applied to 
nanoparticle uptake.
       
 
dC
dt
kC g
i
ii i
i
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(4)
where C is the concentration of the components involved 
in the ligand receptor interaction, k is the kinetic parameter 
and g is the source term. This model considers ligand 
binding to the free surface receptors, internalization of 
ligand-receptor complexes and free receptor recycling and 
degradation, and receptor synthesis in the golgi as rate 
limiting trafﬁ  cking steps.
The primary limitation of kinetic models used to 
describe processes at the cellular level is the number of 
parameters that need to be estimated simultaneously from 
limited experimental data (quantitative data for parameter 
estimation) and a lack of time resolved data for model 
validation. The Lauffenburger and Linderman model, for 
example, contains seven kinetic constants to be determined 
experimentally. A need to enhance the information content 
of the experiments through optimal design of experiments 
using statistical techniques (Munack 1989; Nahor et al 2001) 
or many experimental permutations is therefore, needed. 
For instance, Tzafriri and coworkers (Tzafriri et al 2004) 
attempted to estimate the involved parameters and analyze 
the base model (Lauffenburger and Linderman 1993) by 
designing three different experimental protocols. 
Fewer cell mechanics models of nanoparticle uptake exist. 
Gao and coworkers (Gao et al 2005) modeled the uptake of 
cylindrical and spherical nanoparticles to simulate receptor 
mediated endocytosis by adopting a mathematical frame-
work developed by Freund and Lin (Freund and Lin 2004). 
The Gao model considers a ﬂ  at cell membrane containing 
diffusive mobile receptors that wrap around cylindrical or 
spherical nanoparticles presenting compatible ligands. The 
ligands on the particle are assumed immobile and uniformly 
distributed whereas the receptors are mobile and undergo 
rapid diffusion in the plane of the cell membrane (Figure 4). 
As the receptors of the cell membrane diffuse to the wrapping 
site (adhesion front), the binding of the receptors around the 
particle lowers the free energy of the interaction. 
Considering the global conservation of the receptors, 
their diffusive ﬂ  ux was treated as a diffusion problem in a 
moving front (Stephan problem). A simpliﬁ  ed free energy 
function was employed to account for the energy ﬂ  uctua-
tions as the particle enters or leaves the host cell. The model 
predicted a maximum, optimum and minimum particle sizes 
for receptor-mediated endocytosis, which was in agreement 
with experimental observations. Below the minimum radius 
the wrapping causes an increase in free energy and cannot 
proceed. This minimum for a spherical particle can be derived 
as Equation 5:
        RB E
kT L
RL
BL L
min // l n =− + + 21 00 ξ ξ
ξ
ξ
ξ
   (5)
where B is a numerical factor (between 20–30 for biological 
membranes), ERL is the energy ligand-receptor binding, kB  is 
the Boltzmann constant, T is the absolute temperature, ξL is 
the ligand density, and ξ0 is the initial receptor density on 
the membrane. When particle size exceeds the maximum 
particle size, the wrapping process cannot be completed due 
to a limited number of receptors. 
Although this model is still greatly simpliﬁ  ed relative to the 
real system, the mechanistic approach provides a solid theoretical 
framework upon which a true engineering design approach to 
particle based targeted cellular delivery can be applied.
Computational chemistry 
approaches at the micro and nano 
scales
Methods for conventional DDS 
The characterization of the different interactions such as 
drug-carrier, carrier-medium (biological) and drug-medium International Journal of Nanomedicine 2007:2(3) 322
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are a critical consideration and are often expressed as 
model parameters at the higher space-time scales. Molecular 
modeling and computational chemistry provide a number 
of tools including quantum mechanical ab initio methods, 
molecular dynamics, free energy perturbation and docking 
to quantify these interactions (Neumann et al 2004). Due 
to the extreme complexity of the interactions, however, the 
relationship between chemical and physical properties is 
poorly described. 
The development of empirical formulae, commonly 
referred to as quantitative structure-property/activity 
relationships (QSPR/QSAR), is an attractive approach for 
drug and drug delivery design (Karelson et al 1999). These 
relationships are derived from empirical correlation of 
physico-chemical properties of the drug or carrier molecules 
such as molecular descriptors, lipophilicity, electronic 
properties (eg, steric properties molar refractivity), quantum 
chemical or structural data. These properties can be divided 
into several categories such as constitutional, topological, 
geometric, electrostatic, quantum-chemical, thermodynamic 
and salvation descriptors, depending on the compound and 
property and activity to predict. The origin and deﬁ  nitions 
of these descriptor types and others is extensively described 
in (Katritzky et al 1994, 1996, 1997). Application of QSAR/
QSPR range from prediction of drug pharmacologic activity 
(Gozalbes et al 2002), drug biological activity (Karelson et al 
1996; Karelson 2000; ), drug solubility (Rytting et al 2004), 
to diffusion coefﬁ  cients for polymers (Clement et al 2004). 
The use of empirical molecular descriptors that rely 
on experimental data is limited by the availability of the 
necessary experimental data and can result in complicated 
artiﬁ  cial parameters that are difﬁ  cult to interpret. (Kubinyi 
a
b
S
a(t)
ξL
ξ+
ξ0
ξ (s,t)
Figure 4   An illustration of receptor mediated endocytosis process of particle uptake as modeled by Gao and co-workers (Gao et al 2005) (a) Ligands on the particle 
bind to receptors on initially uniformly distributed receptors on the membrane causing diffusive movement of the mobile receptors (b) The receptor density distribution, 
ξ(s,t), in the membrane becomes nonuniform upon ligand-receptor binding; the receptor density is depleted in the near vicinity of the binding area and induces diffusion 
of receptors toward the binding site. 2*a(t) is the contact area between the particle and the membrane. Gao H, Shi W, Freund LB. 2005. Mechanics of receptor-mediated 
endocytosis. PNAS 102: 9469–74. Copyright © 2005 National Academy of Sciences, USA. International Journal of Nanomedicine 2007:2(3) 323
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2004) argues that prediction by using QSAR models from 
empirical molecular descriptors remains uncertain. An 
alternative is the use of molecular descriptors derived using 
only the information encoded in the chemical structure of 
the compound. (Karelson et al 1999) outline three steps 
for the derivation of the theoretical molecular descriptors 
from the chemical structure of a compound with the aid 
of computer software: 1) input of molecular geometry; 
2) optimization preliminary geometry using molecular me-
chanics; and 3) reﬁ  nement of the 3-D molecular structure 
and calculation of electronic properties of compounds using 
semi-empirical quantum mechanical methods.
Quantum mechanical ab initio methods are the most com-
plex and time-consuming. The density functional theory can 
be mentioned as one of the successful methods to simulate 
few hundred atoms without any experimental input. This 
method together with higher level methods can be a very 
useful tool to investigate and predict the properties of 
emerging nano-based drug delivery systems. The results 
of ab initio calculations are often taken as a reference 
to verify results from other computational methods or 
to calibrate these methods. In contrast to the ab initio 
methods, semi empirical calculations are much less time 
consuming as they try to approximate time consuming 
components of the quantum mechanics calculations by 
simple empirical models. These models are based on 
experimental data (bond length, binding energy, elec-
tronegativity) and thus semi empirical methods have 
problems describing unusual compounds reliably. 
The classical molecular mechanics calculations are even 
less time consuming than semi empirical ones. Here, the 
potential energy of the system is calculated as the sum of a 
set of simple equations. Each so-called force ﬁ  eld uses its 
own values for van der Waals radii, optimal bond lengths, 
etc to describe the molecular mechanics of molecules. 
When compared to quantum mechanical methods, classical 
molecular mechanics is computationally cheap and can thus 
be employed to simulate the dynamic behavior of molecules 
for larger time spans. 
An overview of the ab initio, semi empirical and mo-
lecular mechanics methods is well summarized in (Ghoniem 
and Cho 2002). An extension of the molecular dynamics 
simulation, which is used to quantify relative binding free 
energies of ligands to receptors, is the free-energy pertur-
bation. In addition to the kinetic inﬂ  uences, this method 
primarily considers thermodynamic factors to characterize 
selective binding of molecules to yield different molecular 
complexes in non-equilibrium conditions such as biological 
(cellular) environments. This enables to rank the binding 
free energy in the complex formation of two chemically 
similar and biologically active ligands and thus of particular 
importance in the design of targeted drug delivery systems. 
Detailed information on the method and some applications on 
drug design can be found in the book edited by (Reddy and 
Erion 2001). Moreover, detailed information for the imple-
mentation of the method in molecular dynamics program 
for the computation of free energies is described in Reddy 
et al (Reddy et al 2000). 
A computationally less expensive method for predicting 
ligand-receptor interaction is the molecular docking. Dock-
ing is a molecular process of searching for a ligand that is 
able to ﬁ  t both geometrically and energetically the binding 
site. Usually the best geometries resulting from this process 
are energy minimized and the conformation with the lowest 
energy is further evaluated. The results of molecular docking 
are less accurate compared to the above mentioned methods 
but usually give good idea in ranking the level of interaction 
of ligands with a given receptor (Neumann et al 2004). 
Ab initio, semi empirical and molecular mechanics 
methods are usually not suited for modeling large systems 
like proteins and polymers. For these systems often 
mesoscale modeling techniques that deal with length scales 
(10–100 nm) between the atomistic and engineering scales 
are required (Maiti et al 2004). In this technique subunits 
are deﬁ  ned instead discarding atomistic detail. The selection 
of the subunits depends on the system being modeled such 
as, for instance the monomer of a polymer as opposed to 
molecular model, which builds the monomer atom by atom. 
This method has been applied to drug delivery systems and 
drug diffusivity through cell membrane predictions by Maiti 
et al (Maiti et al 2004).
Application of molecular level prediction 
to nanoparticle DDS 
Naylor et al (Naylor et al 1989) pioneered the study and 
characterization of dendrimers using molecular level mod-
eling and simulation. In this work, the morphological and 
topological structures of dendrimers as a function of genera-
tion were investigated using molecular dynamics to calculate 
the moment of inertia. Simulations indicated that dramatic 
changes in morphology occur with generation number; gen-
erations 1–3 are highly asymmetric whereas generations 5–7 
are nearly spherical with the transition between the two forms 
occurring at generation 4. In addition, average structures 
for the early generations are open, domed shapes, as com-
pared to more dense, spheroid-like topologies for the latter International Journal of Nanomedicine 2007:2(3) 324
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generations with solvent-ﬁ  lled interior hollows connected 
by channels that run the entire length of the macromolecule. 
Generations 4–7, therefore, appear capable of encapsulating 
guest molecules. Bhalgat and Roberts (Bhalgat and Roberts 
2000) expanded this work in 2000 to evaluate the effect of 
chemical modiﬁ  cation on the interaction of the dendrimers 
with the biological target site. Similar efforts carried out using 
Monte Carlo simulation by Mansﬁ  eld and Klushin (Mansﬁ  eld 
and Klushin 1993) resulted in equilibrium values. Although 
the latter lack atomistic details, the longer simulation times 
allow equilibrium values to be obtained, which is very dif-
ﬁ  cult with MD simulations. 
The application of molecular level simulation for the 
design and synthesis of nanoparticle drug delivery device 
was carried out by Quintana et al (Quintana et al 2002). 
They employed molecular dynamics simulation to evaluate 
the biologic function of dendrimer-folate nanodevice by 
applying different capping groups to enhance selective bind-
ing with the receptor. The primary amines on the surface of 
the dendrimer normally result in charge-based non-speciﬁ  c 
interaction diminishing the targeting. Modeling showed that 
capping the primary amines with carboxy groups produced 
local branch aggregation implying intermolecular branch 
interaction. On the other hand capping with 2, 3-dihydroxy 
propyl or acetamide yielded neutral surfaces resulting in the 
overall relaxation of the molecular structure due to absence 
of repulsive forces. Evaluation of the biological activity 
of the dendrimer folate nanodevices experimentally with 
KB (epidermoid carcinoma) cells confirmed the model 
prediction with the acetamide capping group showing the 
highest binding ability. The hydroxyl-surfaced nanode-
vice showed an overall binding capacity similar to the 
acetamide surfaced nanodevice at 2 fold concentration of the 
acetamide-surfaced nanodevice.
Stochastic approaches to 
macroscale (tissue, organ) 
parameter variability 
Human subject variability due to age, pathological state, 
nutritional state, and intrinsic diversity can result in large 
differences in tissue and organ level parameters and lead 
to unacceptable error if models are based on mean param-
eters only. Sources of the inter/intra subject variability in 
the GI tract include the inherent variability of residence 
time of contents in the different GI tract segments, vary-
ing conditions of fed/fast state, or varying or progressing 
pathological state of the GI tract reﬂ  ected as varying pH, 
osmolarity and residence time. There are several approaches 
to deal with the stochastics of this nature: the Monte carlo 
(MC) method, stochastic perturbation analysis and variance 
propagation algorisms. 
In the Monte carlo method, samples of the random pa-
rameters are generated by means of a random generator and 
the corresponding model equations are solved (Fishman 
1996). This procedure is repeated several times and ﬁ  nally 
mean values and variances as well as higher order moments 
are estimated. While the Monte Carlo method yields a rather 
complete picture of the stochastic system, the typically slow 
convergence properties require a large number of runs to 
obtain results with acceptable accuracy. 
The stochastic perturbation method is based on 
the computation of the propagation of an infinitesimal 
perturbation of the (stochastic) parameters during the pro-
cess. In this method the random field of the stochastic 
parameters can be represented in several ways such 
as Taylor expansion, Neuman expansion methods and 
mean values and (co)variances of the process variables 
can then easily be evaluated. In the case where large 
perturbation are present, the spectral expansion methods 
(Ghanem and Kruger 1996) that focus on higher order 
statistics such as the Karhunen-Loeve and the polynomial 
chaos expansion are employed. The method can only be 
applied to problems with random parameters that do not 
change with time. Often the stochastic perturbation equa-
tions are solved using numerical techniques such as FEM. 
This method is applied in transport problems in heat and 
mass transfer (Nicolai and Baerdemaeker 1997), porous 
media flow (Aguirre and Haghighi 2002) and coupled 
heat and mass transfer (Scheerlinck et al 2001). 
The variance propagation algorithm computes the mean 
values and variances of the variable of interest (drug concentra-
tions in drug delivery systems) under processes and environ-
mental parameters that ﬂ  uctuate transiently in a random way. 
Because a complete probabilistic description of the variable of 
interest is difﬁ  cult to obtain, a ﬁ  rst order approximate expres-
sion for the mean vector and the covariance matrix is provided 
from basic stochastic systems theory (Melsa and Sage 1973). 
This method is also of interest because it is based on numerical 
methods such as FEM that can be applied where no analytical 
solutions can be obtained. Although successfully applied to 
similar problems in other ﬁ  elds, such as transport problems of 
heat and mass transfer (Nicolai and Baerdemaeker 1999), the 
stochastic perturbation method and the variance propagation 
algorithm are not yet exploited in the mathematical modeling 
of drug delivery systems.International Journal of Nanomedicine 2007:2(3) 325
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Case study: Multiscale modeling 
of targeted oral drug delivery 
to the colon
Oral drug delivery targeted to the colon is important for 
both the treatment of local disorders of the colon and 
for the potential delivery of protein and peptide drugs 
into the body via the colon. In both cases the drug must 
survive the harsh environment of the upper GI tract with a 
maximal payload delivery at the colon. Many approaches 
to this problem are based on the utilization of the varying 
physiological conditions such as pH along the GI tract 
to prevent release until arrival at the colon. Variability 
between patients, in disease progression, in fed-fasted 
state, in tablet properties and in tablet geometry, all 
complicate the practice of these approaches. 
In an effort to provide clinically relevant predictions using 
a more realistic computational model for the delivery to the 
colon, we developed a drug release model for targeted oral 
drug delivery systems based on the multiscale framework 
presented in section 3 (Haddish-Berhane et al 2006b). The 
commercially available targeted delivery system, Asacol®, 
which delivers 5-aminosalicyclic acid (5-ASA) to the colon, 
served as the drug subject. The Asacol® tablet contains a 
core of 400 mg of mesalamine coated with pH-sensitive 
anionic copolymers of methacrylic acid and methyl methac-
rylate called Eudragit®-S (Röhm GmbH & Co. KG, Pharma 
Polymers, Darmstadt, Germany), which delay release of 
mesalamine until the tablet reaches an environment of pH 7 
or above. 
A continuum approach was pursued to model the drug 
diffusion and coating erosion by considering the relevant 
geometry of the delivery device using the mathematical 
description given in Equation (1). The source term in this 
equation results from drug dissolution in this particular case 
and was expressed by the Whitney-Noyes equation (Equa-
tion 6).
  Rk A c v = () Δ pH  
(6)
where k is the dissolution rate constant, which is a function 
of a stochastic variable pH; Av is the surface area per unit 
volume; and ∆c = cs – c, the driving force for the dissolution 
of the drug where cs is the solubility of the drug. The dissolu-
tion of the polymeric coating as a function of GI transit time 
and pH poses a moving boundary problem, addressed using 
Arbitrary lagrangian-eulerian (ALE) approach (Donea et al 
2004). A stochastic Monte Carlo method was employed to 
incorporate the effect biological variability in the GI tract on 
the drug release behavior in the model. The pH-dependent 
dissolution rate constant of the coating polymer was con-
sidered to be a random parameter sampled from a normal 
distribution and a Monte carlo (MC) simulation (Fishman 
1996) was performed.
The interaction of the drug molecule (5-amino, 
2-hydroxybenzioc acid) with water was investigated using 
MD simulation to predict the diffusion properties of the 
drug. After obtaining the topology of the involved molecules 
using PRODRG (Schuttelkopf and van Aalten 2004) MD 
simulations were carried out using GROMACS (Lindahl and 
van der Spoel 2001). To compute the diffusion coefﬁ  cients, 
the Einstein relation based upon Mean Square Displacement 
was used. Parameters that characterize the interaction of the 
polymeric coating with the medium were derived from free 
volume theory (Flory 1953).
Prediction of coating dissolution 
dynamics
Coating dissolution of the tablet as it transits the GI tract is 
a key factor on timely and targeted release of the payload at 
the delivery site. Thus, prediction of the coating dissolution 
during transit in the GI tract provides important information 
on the performance of the delivery system. Figures 5(a) and 
5(b) show the predicted dissolution of the polymeric coat-
ing in different intestinal buffers qualitatively and quantita-
tively, respectively as the tablet transits through the stomach 
(pH =1.2), proximal intestine (pH = 6.8) and distal intestine 
(pH = 7.2). The simulations conﬁ  rmed that dissolution of 
the coating was almost non-existent at low pH environ-
ments (stomach) and takes place at a high rate in the distal 
segment of the intestine as the pH progressively increases. 
72% of the coating dissolved in approximately 15 min as the 
tablet reached the distal intestine. Experimental in vitro data 
validated the predicted drug release kinetics with favorable 
agreement with in 5% mean square error.
Drug release kinetics and biological 
variability
Often, the efﬁ  cacy of the delivery systems for the topical 
treatment of colonic diseases is hampered by inter/intra-
subject variability in the GI tract environment. Theoretical 
investigation using the model considered experimentally 
observed variability in healthy and diseased (Ulcerative 
colitis) subjects obtained from literature. To demonstrate 
the importance of the multiscale tool to obtain clinically International Journal of Nanomedicine 2007:2(3) 326
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relevant predictions, here results from diseased subjects will 
be summarized. Details can be found in Haddish-Berhane 
et al (Haddish-Berhane et al 2006a).
Subjects with ulcerative colitis (UC) 
In the case of diseased subjects, three drug release patterns also 
resulted from the numerical experiment (400 MC runs) where 
drug release occurred in i) the distal small bowel only; ii) the 
distal small bowel and colon; and iii) the colon or excreted 
intact. The variation in drug release ranged from 0% to 100% 
at the target site (distal intestine/proximal colon) as a result 
of variation in pH and transit time. The overall average drug 
release in the distal part of the intestine stands at 48% with 95% 
conﬁ  dence interval of 20%. The relatively larger conﬁ  dence 
interval associated with the diseased subjects is as a result of 
the higher observed variability in the pH and transit time in 
the distal intestine. For the pH range considered, the average 
drug release varies from 30–55% (Figure 6a). This variation 
shows the spread expected due to distal intestine transit time 
variability. The drug release due to distal intestine pH vari-
ability ranges from 0–100% (Figure 6b). Here, the conﬁ  dence 
intervals, which show the uncertainty due to variability in 
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Figure 6 (a) The average drug release in the distal intestine versus the distal transit time for subjects with UC. Each data point is the average of the cumulative drug release 
of all the pH values randomly sampled at the end of the gastric and intestinal residence time. (b) The average drug release versus pH in the distal intestine for UC patients. 
The error bars represent the 95% conﬁ  dence interval with respect to the pH and intestinal transit time variability, respectively. 
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Figure 5 Simulation of the polymeric coating (EudraGI tract® S-100) of Asacol® (a) enlarged section of the interface between the drug core and coating at t = 0 h; (b) after 
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transit time, are smaller than that of the pH. This implies that 
pH is a dominant factor that inﬂ  uenced the drug release at the 
target site. The payload that was delivered to the colon and that 
entered the systemic circulation, calculated from the predicted 
release, agreed favorably with reported clinical results. 
The characteristic curves generated from the model results 
(Figure 6) can be produced for other delivery systems. These 
characteristic curves can be used for design purposes to 
improve the performance of the dosage forms. Moreover, 
physicians can use these characteristic curves and the pH and 
transit time proﬁ  le of their patient to determine and prescribe 
a dosage form and treatment regimen that would work best 
for that specific patient. Even though similar evaluation 
results for a range of oral targeted delivery systems exist from 
in-vivo (clinical) evaluations, this example demonstrates that 
computational modeling could provide clinically relevant 
information, which can be used for the rational design of the 
delivery system.
Current state of DDS multiscale 
modeling
Computational approaches to evaluate, design and optimize the 
conventional drug delivery systems have not yet gained wide-
spread acceptance and conﬁ  dence by the pharmaceutical and 
research community. Although several factors have contributed 
to this current reality, including infrastructural and organizational 
issues (Grasela et al 2005), the limited predictive ability and ac-
curacy of existing mathematical models plays a signiﬁ  cant role. 
(Rhodes and Porter 1998) and similarly (Boobis et al 2002) argue 
that many models are often insufﬁ  cient to predict the in vivo dis-
solution and release rates reliably and precisely. This limited pre-
dictive ability, we believe, can largely be attributed to either one 
of two problems. Comprehensive approaches that strive to model 
the entire system typically rely on the use of simple empirical or 
semi-empirical models, which are not truly sufﬁ  cient to predict 
the essential behavior of the interaction of drug and its carrier. On 
the other hand, more complex, mechanistic theories and models 
focus on one particular process, but are not yet coupled to other 
physical, chemical or biological processes that are critical in the 
real system. The establishment of multiscale methods that can 
integrate processes across spatial scales is required to describe 
the complete system mechanistically.
Certainly multiscale modeling has been applied to nanopar-
ticle problems such as prediction of dendrimer interactions 
with different solvents (Cagin et al 2001). We are unaware of 
any multiscale modeling studies that have integrated mecha-
nistic models across the scales to predict both the uptake and 
transport process of the nanoparticles (nano/micro to macro 
level) and the response of the involved organs (atomic to or-
gan level scales). Fundamental mechanisms at each isolated 
scale are still new territories themselves. As progress is made 
in understanding the mechanisms of nanoparticle interaction 
with cells and tissues and in the multiscale modeling of con-
ventional drugs, the application of this and similar frameworks 
to nanoparticle DDS is sure to follow.
Future directions and implications
Need for measurement techniques and 
experimental paradigms 
Mechanistic approaches to modeling depend upon the 
quantity, quality and form of existing experimental data 
as well as the possible experimental paradigms available 
for estimating parameters and validating models. Acqui-
sition of temporally and spatially resolved data to track 
levels of molecules and nanoparticles in living cells and 
organisms remains an important technological challenge 
along side the modeling challenges that are highlighted 
in this review. In general four types of experimental data 
and systems are needed for the further advancement of 
the computational modeling: 1) time-resolved spatial 
data in living cells, tissues and organisms; 2) data sets 
from experiments designed to optimally extract param-
eter estimates from the measurable variables; 3) novel in 
vitro paradigms for simulating more realistic physiologi-
cal conditions in controlled environments; and finally 
4) statistical distribution data characterizing physiological 
and delivery system variability.
The ability to track detailed physiological and transport 
events in single cells or whole tissues over time is critical 
for building and testing realistic models. For example, meth-
ods such as multiple particle tracking have enabled the real 
measurement of nanoparticle transport rates and diffusion 
coefﬁ  cients in gastric mucosal layers (Dawson et al 2004). 
Sensing systems for spatially and temporally resolved cellular 
data, however, are not widespread and much more develop-
ment is needed. This is an area in which novel cytomic and 
physiological sensing capabilities can contribute signiﬁ  cantly 
to computational models. 
Novel in vitro paradigms that can simulate the effects 
of physiological parameters under controllable conditions 
are needed to compliment the time resolved measurement 
systems. A recent example of such an experimental paradigm 
uses a microﬂ  uidic device built by Farokhzad et al (Farokhzad 
et al 2005) to study the effects of shear stress on the speciﬁ  c 
and non-speciﬁ  c binding of polymeric nanoparticles to cells International Journal of Nanomedicine 2007:2(3) 328
Haddish-Berhane et al
expressing the cancer associated prostate speciﬁ  c membrane 
antigen. The advantage of such a system is that physical 
conditions such as ﬂ  ow in the microvasculature can be 
simulated to measure model parameters in vitro that would 
be more difﬁ  cult and expensive to measure in vivo. By esti-
mating parameters for use in larger scale model components 
and validating model predictions from smaller scale model 
components, the multiscale modeling can then provide a 
quantitative and testable link between less expensive cell 
culture studies and more resource associated in vivo biodis-
tribution studies.
Establishing methods for the rigorous control of nanopar-
ticle properties such as size, composition, and morphology 
are a primary goal for developing new nanomaterials and 
methods (Rolland et al 2005). Understanding the effects of 
variability and distribution of nanoparticles as well as con-
ventional delivery vehicles, however, will continue to be 
important if such particle technologies intend to advance to 
clinical stages and industrial production. Certainly stochastic 
modeling components within multiscale models and statistical 
distribution data of experimentally measured delivery vehicle 
properties and physiological conditions will be critical.
Application to safety 
Nanoparticles are designed for biological interactions but 
we have little experience or data (relative to single mole-
cule drugs) regarding those interactions in organisms. The 
safety of producing, handling, and using nanoparticles is 
therefore an issue of major importance to the field (Ober-
dorster et al 2005). As the diversity of new nanoparticle 
materials increases, the ability to experimentally test all 
particles in an in vivo system becomes unrealistic. The 
use of mechanistic models, such as those proposed here, 
that are based on nanoparticle physiochemical properties 
could be a powerful tool, in addition to in vitro and in vivo 
models, for classifying nanoparticles in terms of safety. 
Models of oral delivery will be particularly applicable to 
safety as the GI tract is one of the major exposure points 
for nanoparticles to enter the body.
Evolution of existing and 
development of novel multiscale 
approaches 
The projection that by 2016 about 30% of pharmaceutical 
R&D expenditure will be on computer simulation (Anderson 
2002) connote that we will see more and more mechanistic 
models developed. Multiscale computational modeling 
approach for rational design of drug delivery systems, 
however, is in its infancy even for the conventional drug 
delivery systems. Due to the permutations of the confound-
ing factors that complicate the traditional experimental (wet 
lab) approach, the need for multiscale computational models 
is even higher for the design of drug delivery systems of 
nanoparticles that involve multiscale processes both in the 
spatial and temporal dimensions. Thus, a pathway to future 
designs of smart delivery systems will be integration of 
the different elements at various levels of scales involving 
the physico-chemical and biological phenomena.
The multiscale problem involved in DDS is that of the 
drug delivery device and that of the biological environment 
with which it interacts. Modeling efforts concerning the 
device so far have focused on bringing the disparate scales 
using purely empirical, not easily understood relationships in 
the translation from one level to the other. Such approach is 
pursued in the QSAR models. This arises from the time and 
length limitations in terms of obtaining adequate information 
for prediction of macroscale properties from atomistic simu-
lations. Development of advanced multiscale approaches will 
thus investigate the intermediate levels above and below the 
disparate scales in order to bridge the gap using mechanistic 
approach. 
On the other hand, the biological environment and its 
interaction with the xenobiotics should be represented 
from subcellular to organ level which involves disparate 
length and time scales. Besides connecting scales with 
parameters and coupling coefficients efforts towards 
bridging this scale gap will focus on merging the discrete 
atomistic level processes with the continuum at the higher 
levels and the coupling of the processes at different time 
scales within the different scales. The challenge here 
arises from the non-linear relationship between the scales. 
That is, the average behavior exhibited at the macroscales 
dramatically differs from the subscales (eg, metabolism). 
This will take development of advanced coarsening and 
refinement schemes both for time and length scales that 
must take key microscale phenomena such as bifurcation 
and seamless meshing/discretization techniques at the 
interface of the scales.
Other mathematical related problems that need to be 
addressed to produce fully predictive models will be the 
propagation of errors as the different scales are bridged. In 
case of multiscale simulation the sources of error include 
models selected at each scale, parameters used in each 
model, solution transfer errors, equation discretization 
and nonlinear equation solution errors (Shephard 2004). International Journal of Nanomedicine 2007:2(3) 329
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Hence, the development of useful error estimators correc-
tion indicators for the various components of the multiscale 
framework using existing adaptive approaches need to be 
accelerated. 
Finally, multiscale approaches are not as widely applied 
in the drug delivery ﬁ  eld as in other ﬁ  elds such as materials 
science and engineering. The reason for this is that each 
level in the mechanisms of drug delivery (Figure 1) is vast, 
involving complex network of dynamically interacting 
heterogeneous components. The design of drug delivery 
devices can utilize and beneﬁ  t from the application of 
the multiscale modeling for the rational design of smart 
delivery systems.
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